

## Supplementary Table S1. Raw data of the heatmap presented in Figure 1A

EXPERIMENT : Seinsitization to Prexasertib (100 nM)

ENDPOINT : Evaluation of % of viable cells by CellTiter Glo 72h upon treatment

NOTE : Number of independent experiments (n) =3

For each independent experiment, the results are normalized over untreated/control condition.

			Independent experiments			Mean
			1	2	3	
Target	<b>RAD51</b>	Untreated (NT)	100	100	100	100
Drug	<b>B02</b>	Prexasertib	92	101	84	92
Concentration	10 $\mu$ M	B02	81	72	76	76
		Prexasertib + B02	50	50	52	51
Target	<b>MRE11</b>	NT	100	100	100	100
Drug	<b>Mirin</b>	Prexasertib	93	76	82	84
Concentration	25 $\mu$ M	Mirin	92	93	67	84
		Prexasertib + Mirin	74	59	42	58
Target	<b>Topoisomerase I</b>	NT	100	100	100	100
Drug	<b>Irinotecan</b>	Prexasertib	102	94	102	100
Concentration	1 $\mu$ M	Irinotecan	94	84	95	91
		Prexasertib + Irinotecan	65	67	79	70
Target	<b>WEE1</b>	NT	100	100	100	100
Drug	<b>Adavosertib</b>	Prexasertib	87	79	97	88
Concentration	100 nM	Adavosertib	77	70	102	83
		Prexasertib + Adavosertib	37	25	40	34
Target	<b>RRM2</b>	NT	100	100	100	100
Drug	<b>Triapine</b>	Prexasertib	88	89	94	91
Concentration	200 nM	Triapine	101	89	116	102
		Prexasertib + Triapine	30	27	19	25
Target	<b>ATR</b>	NT	100	100	100	100
Drug	<b>VE-821</b>	Prexasertib	79	85	96	87
Concentration	15 $\mu$ M	VE-821	68	75	84	76
		Prexasertib + VE-821	60	75	80	72
Target	<b>DNA-PK</b>	NT	100	100	100	100
Drug	<b>NU7026</b>	Prexasertib	85	86	87	86
Concentration	50 $\mu$ M	NU7026	88	88	94	90
		Prexasertib + NU7026	81	79	86	82
Target	<b>ATM</b>	NT	100	100	100	100
Drug	<b>KU-60019</b>	Prexasertib	87	89	83	86
Concentration	5 $\mu$ M	KU-60019	78	91	86	85
		Prexasertib + KU-60019	76	78	77	77